Eli Lilly and Company (LLY)
Eli Lilly and Company is a U.S.-based pharmaceutical company that discovers, develops, manufactures, and markets human medicines in the United States, Europe, China, Japan, and other international markets. Its portfolio spans cardiometabolic care, oncology, immunology, and neuroscience. Key products in cardiometabolic health include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, and Zepbound. In oncology, the company markets therapies such as Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, TYVYT, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz, while Emgality is used for migraine prevention and episodic cluster headache and Kisunla is indicated for symptomatic Alzheimer’s disease. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly maintains collaborations and licensing arrangements with several pharmaceutical partners, including Boehringer Ingelheim, Roche, Genentech, Almirall, and Chugai Pharmaceutical.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-LLY
|
$1,207
|
3.9% Upside
|
Fair
|
$1,270
|
9.3% Upside
|
Fair
|
Great
|
August 14, 2026
|
September 10, 2026
|
6.92
|
0.6%
|
August 5, 2026
|
41.0x
|
33.2x
|
14.3x
|
1,022.7 B
|
1,073.8 B
|
4.1%
|
99.7%
|
9.6
|
22.1%
|
46.8%
|
